Clinical Trials
48
8 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1964
Active, not recruiting
5
10.4%
Completed
26
54.2%
Not yet recruiting
3
6.3%
Recruiting
8
16.7%
Terminated
3
6.3%
Unknown
1
2.1%
Withdrawn
2
4.2%
No approval data available
- Researchers identified a distinct subgroup of highly functional CAR T cells whose abundance correlates directly with the success of low-dose CAR T-cell therapy. - The absolute number of these specific cells could serve as a future biomarker for predicting treatment response, even when overall cell counts are low. - The state of a patient's immune system before cell manufacturing begins also influences whether effective CAR T-cell products can be generated. - Findings, published in Nature Communications, could further personalize cancer immunotherapy and help conserve costly healthcare resources.
- An international study published in Nature demonstrates that germline genetic background profoundly dictates cancer evolution trajectory, driver mutation selection, and tumor latency in experimental liver cancer. - Researchers examined over 580 liver tumors across four genetically distinct mouse strains exposed to identical carcinogens, finding strain-specific preferences for activating mutations in Braf, Hras, Egfr, and Kras. - Highly susceptible genetic backgrounds required only a single driver event for malignant transformation, while resistant backgrounds needed multiple driver alterations and experienced early subclonal lineage loss. - The findings underscore the importance of incorporating germline-somatic epistasis into personalized cancer prevention, early detection, and treatment strategies.
- Moritz Mall's SafeCure project aims to equip glioblastoma cells with the neuronal transcription factor MYT1L to lock them in a low-plasticity, treatment-sensitive state. - The "lock-and-kill" strategy uses MYT1L to stabilize cancer cells in a vulnerable state so chemotherapy and radiotherapy can kill them persistently. - AI-identified cancer-cell-specific enhancers will direct MYT1L activity exclusively to glioblastoma cells, minimizing off-target effects. - The project targets an investor-ready preclinical package to enable pharmaceutical companies to advance SafeCure toward first-in-human use.
- A 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with Immatics' PRAME-directed TCR T-cell therapy at KiTZ in Heidelberg. - The patient had rapidly progressing disease with brain, liver, and lung metastases and had exhausted all available treatment options before receiving the experimental therapy. - PET scan and MRI imaging demonstrated marked tumor regression across all lesion sites, with molecular remission confirmed by liquid biopsy showing no tumor-derived DNA. - The response remained ongoing at six months of follow-up, with the patient in excellent physical condition despite manageable cytokine release syndrome during treatment.
- Two independent research teams have developed nanoparticle-based therapeutic vaccines that successfully suppressed HPV-related tumors in preclinical mouse models, addressing a critical gap in treatment for existing HPV-associated cancers. - The UT Southwestern nanovaccine achieved remarkable efficacy in metastatic disease, with 71% survival at 60 days compared to zero survival with current standard checkpoint inhibitors alone, and 100% survival when combined with checkpoint therapy. - Both vaccine platforms utilize different nanoparticle carriers to deliver HPV antigens and immune stimulants, demonstrating the versatility of nanotechnology approaches for cancer immunotherapy. - The therapeutic vaccines target patients with established HPV-related cancers such as cervical and head-and-neck cancers, where preventive HPV vaccines offer no benefit and treatment options remain limited.
